RA Capital Management - a stockholder and director-level investor that owned roughly ten percent of Vor Biopharma Inc (NASDAQ: VOR) - completed a block of sales totaling 619,333 shares of common stock between April 8 and April 10, 2026. The aggregate proceeds from those dispositions were approximately $10.2 million.
The sales were executed over multiple transactions and broken down as follows:
- April 8: 353,242 shares sold at a weighted average price of $16.32, with individual transaction prices ranging from $15.755 to $16.68.
- April 8: a second set of 130,862 shares sold the same day at a weighted average price of $16.91, with prices in the $16.755 to $16.975 range.
- April 9: 135,201 shares sold at a weighted average price of $16.59, with transaction prices between $15.94 and $16.385.
- April 10: 828 shares sold at a weighted average price of $15.75, with transaction prices between $15.75 and $15.76.
Following these dispositions, RA Capital Healthcare Fund L.P. indirectly held 3,935,608 shares of Vor Biopharma common stock.
The sales took place against a recent pullback in Vor Biopharma's market price - the shares declined 14% over the prior week and were trading at $15.47 at the cited level. Independent valuation analysis from InvestingPro cited in the same reporting indicated a Fair Value estimate for the stock of $18.93 and noted that the platform tracks 12 additional ProTips for investors in VOR.
Separately, Vor Biopharma has been active on both the clinical and financing fronts. The company reported dosing the first patient in a phase 3 trial of telitacicept for Sjögren's disease. That trial is planned to enroll approximately 250 adult patients and will evaluate changes in disease activity over a 48-week period.
On the capital markets side, Vor Biopharma recently raised $75 million through a private placement, selling just over five million shares at $14.05 apiece. Management indicated that the financing is part of a plan to extend the company's financial runway into early 2029. The company has raised more than $330 million in equity capital within a five-month period, according to the noted figures.
Market analysts have continued to follow the company amid these developments. Stifel maintained a Buy rating on Vor Biopharma but adjusted its price target from $55 to $40, citing revised financing assumptions as the reason for the change. Jefferies initiated coverage with a Buy rating and set a $50 price target, calling attention to Vor Biopharma's strategic emphasis on autoimmune indications.
These transactions and corporate updates provide a snapshot of an evolving situation: a major investor trimming shares over a short window, ongoing internal clinical progress, and active capital raises designed to lengthen runway. Each element - insider selling, trial advancement, and fresh equity issuance - will be watched by investors and analysts as they assess the stock's trajectory and the firm's execution on clinical and financial plans.